Shield announces results from it’s Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application for Feraccru.

6 Apr 2018

Shield Therapeutics announces results from it’s Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application for Feraccru. This press release provides a strategic review update and announces the appointment of a Non-Executive Director.  For further details please see the press release attached.

STX_CKD Update from FDA post pre-NDA meeting

Webcast and conference call for analysts at 1pm BST today

Carl Sterritt, Chief Executive Officer, Dr Karl Keegan, Chief Financial Officer and Dr Mark Sampson, Chief Medical Officer, will host a live conference call and webcast for analysts at 1pm BST today, 6 April 2018, to discuss this announcement.

Dial in details:

Location Purpose Phone Number
United Kingdom Participant +44 (0)330 336 9105
United States Participant +1 646-828-8156

The participation code is: 8668739

To access the audio webcast, please follow this link or alternatively visit our  investor relations page.

Back to news

London, UK

120 New Cavendish Street
London
W1W 6XX

t+44 (0) 207 186 8500

einfo@shieldtx.com

Newcastle, UK

Northern Design Centre
Baltic Business Quarter
Gateshead Quays, NE8 3DF

t+44 (0) 191 511 8500

einfo@shieldtx.com

Wollerau, Switzerland

Sihleggstrasse 23,
8832 Wollerau
Switzerland

t+41 (0) 435 080 781

einfo@shieldtx.com

Munich, Germany

München 5 Höfe
Theatinerstrasse 11
DE- 80333 München

t+49 (0) 89 710 42 2246

einfo.de@shieldtx.com